The association of breast mitogens with mammographic densities

[1]  D. Yee.  The insulin-like growth factors and breast cancer — revisited , 1998, Breast Cancer Research and Treatment.

[2]  M. Pollak.  Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention , 1998, Breast Cancer Research and Treatment.

[3]  N F Boyd,et al.  Growth factors and stromal matrix proteins associated with mammographic densities. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  C M Rutter,et al.  Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. , 2001, JAMA.

[5]  J. Brisson,et al.  Tamoxifen and mammographic breast densities. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  D. Venzon,et al.  Effect of tamoxifen on mammographic density. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  W. Willett,et al.  Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. , 2000, Cancer research.

[8]  A. Bartke,et al.  Effects of growth hormone overexpression and growth hormone resistance on neuroendocrine and reproductive functions in transgenic and knock-out mice. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[9]  R. Warren,et al.  Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  B. V. VON Schoultz,et al.  Mammographic breast density during hormone replacement therapy: differences according to treatment. , 1999, American journal of obstetrics and gynecology.

[11]  R. Frairia,et al.  Estradiol induction of cAMP in breast cancer cells is mediated by foetal calf serum (FCS) and sex hormone-binding globulin (SHBG) , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  J. Manson,et al.  Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. , 1999, Journal of the National Cancer Institute.

[13]  S. Cummings,et al.  Elevated Serum Estradiol and Testosterone Concentrations Are Associated with a High Risk for Breast Cancer , 1999, Annals of Internal Medicine.

[14]  M. Thorén,et al.  Determinants of circulating insulin-like growth factor-I. , 1999, Journal of endocrinological investigation.

[15]  A. Boccuzzi,et al.  Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features , 1999, Journal of endocrinological investigation.

[16]  N. Boyd,et al.  Mammographic densities and breast cancer risk. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[18]  D. Leroith,et al.  Growth hormone treatment induces mammary gland hyperplasia in aging primates , 1997, Nature Medicine.

[19]  R. Considine.  Weight regulation, leptin and growth hormone. , 1997, Hormone research.

[20]  K. Chihara,et al.  Effect of natural menopause on serum levels of IGF-I and IGF-binding proteins: relationship with bone mineral density and lipid metabolism in perimenopausal women. , 1997, European journal of endocrinology.

[21]  R. Pasquali,et al.  Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group. , 1997, Metabolism: clinical and experimental.

[22]  N F Boyd,et al.  Symmetry of projection in the quantitative analysis of mammographic images , 1996, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[23]  N. Boyd,et al.  Automated analysis of mammographic densities. , 1996, Physics in medicine and biology.

[24]  J. Veldhuis.  Gender differences in secretory activity of the human somatotropic (growth hormone) axis. , 1996, European journal of endocrinology.

[25]  J. Wolfe,et al.  Mammographic features and breast cancer risk: effects with time, age, and menopause status. , 1995, Journal of the National Cancer Institute.

[26]  M. Wabitsch,et al.  The role of growth hormone/insulin-like growth factors in adipocyte differentiation. , 1995, Metabolism: clinical and experimental.

[27]  P. Strax,et al.  A prospective study of endogenous estrogens and breast cancer in postmenopausal women. , 1995, Journal of the National Cancer Institute.

[28]  H. Adlercreutz,et al.  Regulation of production and secretion of sex hormone-binding globulin in HepG2 cell cultures by hormones and growth factors. , 1995, The Journal of clinical endocrinology and metabolism.

[29]  D. Leroith,et al.  Insulin-like Growth Factors and Cancer , 1995, Annals of Internal Medicine.

[30]  M. Metka,et al.  The role of prolactin in the menopause. , 1994, Maturitas.

[31]  N. Boyd,et al.  The quantitative analysis of mammographic densities. , 1994, Physics in medicine and biology.

[32]  W. Ruan,et al.  Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Carlsson,et al.  High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[34]  R. Bouillon,et al.  Serum levels of growth hormone‐binding protein and insulin‐like growth factor‐I during puberty * , 1992, Clinical endocrinology.

[35]  M. Pollak,et al.  Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. , 1992, European journal of cancer.

[36]  A. Herington.  Insulin-like growth factors: biochemistry and physiology. , 1991, Bailliere's clinical endocrinology and metabolism.

[37]  D. Yee,et al.  The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer. , 1991, Cancer treatment and research.

[38]  C. Redmond,et al.  Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. , 1990, Journal of the National Cancer Institute.

[39]  S. Plymate,et al.  Regulation of sex hormone-binding globulin production by growth factors. , 1990, Metabolism: clinical and experimental.

[40]  B. Hart,et al.  Age and race related changes in mammographic parenchymal patterns , 1989, Cancer.

[41]  I. Fentiman,et al.  The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. , 1988, European journal of cancer & clinical oncology.

[42]  P. C. Johns,et al.  X-ray characterisation of normal and neoplastic breast tissues. , 1987, Physics in medicine and biology.

[43]  R. Furlanetto,et al.  A longitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt. , 1987, American journal of diseases of children.

[44]  D. Anderson,et al.  Serum steroid binding proteins and the bioavailability of estradiol in relation to breast diseases. , 1985, Journal of the National Cancer Institute.

[45]  J. Grove,et al.  Factors associated with mammographic pattern. , 1985, The British journal of radiology.

[46]  H. Collette,et al.  Breast cancer risk associated with reproductive factors and breast parenchymal patterns. , 1984, Journal of the National Cancer Institute.

[47]  G. Hammond,et al.  A versatile method for the determination of serum cortisol binding globulin and sex hormone binding globulin binding capacities. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[48]  F Merletti,et al.  The relation of mammographic features of the breast to breast cancer risk factors. , 1982, American journal of epidemiology.

[49]  J. C. Porter,et al.  Role of estrogen in the dopaminergic control of prolactin secretion. , 1981, Endocrinology.

[50]  P. Lebech,et al.  The effect in post-menopausal women of natural human and artificial oestrogens on the concentration in serum of prolactin. , 1980, Acta endocrinologica.

[51]  E. Adashi,et al.  Stimulatory effect of 2-hydroxyestradiol on prolactin release in hypogonadal women. , 1980, The Journal of clinical endocrinology and metabolism.

[52]  J. Winter,et al.  Pituitary-ovarian relationships preceding the menopause , 1977 .

[53]  J. Nelson,et al.  Observations on the surface area of the abnormal transformation zone associated with intraepithelial and early invasive squamous cell lesions of the cervix. , 1977, American journal of obstetrics and gynecology.

[54]  H. Friesen.  The role of prolactin in breast cancer. , 1976, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[55]  S. Yen,et al.  Augmentation of prolactin secretion by estrogen in hypogonadal women. , 1974, The Journal of clinical investigation.